These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9258314)

  • 1. Monoamine oxidase inhibitors and cardiac anesthesia revisited.
    Noorily SH; Hantler CB; Sako EY
    South Med J; 1997 Aug; 90(8):836-8. PubMed ID: 9258314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 3. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
    Ritter JL; Alexander B
    Ann Clin Psychiatry; 1997 Mar; 9(1):7-13. PubMed ID: 9167831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

  • 7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Churchyard A; Mathias CJ; Boonkongchuen P; Lees AJ
    J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):228-34. PubMed ID: 9285463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
    LeWitt PA
    Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
    Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.
    Ito D; Amano T; Sato H; Fukuuchi Y
    J Neurol; 2001 Jun; 248(6):533-4. PubMed ID: 11499649
    [No Abstract]   [Full Text] [Related]  

  • 15. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
    Youdim MB; Riederer PF
    Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
    [No Abstract]   [Full Text] [Related]  

  • 16. A hypertensive reaction induced by concurrent use of selegiline and dopamine.
    Rose LM; Ohlinger MJ; Mauro VF
    Ann Pharmacother; 2000 Sep; 34(9):1020-4. PubMed ID: 10981248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
    Müller T; Riederer P; Grünblatt E
    J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.